Well-crafted policies and guidelines will help all people living with hemophilia–regardless of their geography, age, gender, or socioeconomic status– to access comparable care and treatment innovation. Without equitable policies, people living with hemophilia may not receive the diagnosis and treatment that they need, impeding their ability to receive optimal care. Guidelines and policy reform, therefore, play a critical role in shaping the future of hemophilia care.
Join us for the final 2024 Hemophilia Changemakers event, in partnership with Sanofi, where we will examine the drawbacks to current global hemophilia guidelines and discuss ways you can effectively advance policy reform. During this event, we will:
"The hemophilia and other bleeding disorders community is experiencing new medications for better and more effective care of patients. Scientific evidence, HCPs' experience, and data are available. It is up to the leaders of this community to adjust to the speed of progress and effectively advocate to get decision makers to think about equitable treatment for all."
• Members of the global hemophilia advocacy community
• Members of the global rare disease advocacy community
• Hematologists / Paediatric Hematologists / Hematologist-Oncologists
• Health/Rare disease policymakers and NGOs
• Patients, family members and carers of those affected by hemophilia
• Industry stakeholders in hemophilia and other rare diseases/trade associations
• Payers and regulators